Inogen (INGN) Insider Purchase: CFO Acquires 1,500 Shares via ESPP
Rhea-AI Filing Summary
Michael J. Bourque, EVP, CFO & Treasurer of Inogen Inc. (INGN), acquired 1,500 shares of the company's common stock on 09/01/2025 at a price of $7.99 per share under the 2014 Employee Stock Purchase Plan. After the purchase, Mr. Bourque directly beneficially owned 49,146 shares. The Form 4 was executed by Mary Wright as Attorney-in-Fact and dated 09/03/2025. The filing indicates the transaction was reported under Section 16 and that the purchase was made pursuant to a company plan; no derivatives, dispositions, or additional transactions are reported on this form.
Positive
- Officer participation in ESPP: The CFO participated in the company's 2014 Employee Stock Purchase Plan, acquiring 1,500 shares at $7.99.
- Timely, proper reporting: Transaction reported on a Form 4 with Attorney-in-Fact signature dated 09/03/2025, indicating compliance with Section 16 disclosure rules.
Negative
- None.
Insights
TL;DR: Insider purchase of 1,500 shares via ESPP; small size relative to total holdings, limited market impact.
The Form 4 documents a routine acquisition under Inogen's 2014 Employee Stock Purchase Plan by a senior executive. The report shows a cash purchase of 1,500 shares at $7.99, increasing direct holdings to 49,146 shares. This transaction is recorded as a non-derivative acquisition and does not include dispositions or option exercises. From a financial perspective, the purchase size and method (ESPP) suggest compensation-related participation rather than a large, discretionary open-market buy; the filing provides no information about intent beyond plan participation.
TL;DR: Routine Form 4 disclosure of an ESPP purchase by an officer; properly reported and signed by attorney-in-fact.
The filing identifies Michael J. Bourque as an officer (EVP, CFO & Treasurer) and reports a straightforward acquisition of common stock through the company ESPP. The Form 4 indicates compliance with Section 16 reporting requirements and includes an Attorney-in-Fact signature dated 09/03/2025. There are no related-party transactions, amendments, or indications of unusual timing in the filing. The disclosure is complete for the single reported transaction and includes the standard explanatory note that shares were acquired under the 2014 ESPP.